As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Bitcoin has fluctuated within a narrow range in recent sessions, reflecting investor caution in an uncertain macroeconomic ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

At 11:26 a.m. ET, the Dow Jones Industrial Average fell 75.92 points, or 0.17%, to 44,797.36, the S&P 500 gained 14.66 points ...

The S&P 500 and the Nasdaq ended higher while the Dow closed lower after a choppy trading session on Thursday, as investors sifted through earnings reports and awaited Amazon's results after the bell ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Wall Street drifted through a mixed day of trading as rising fashion and cigarette stocks worked against drops for Ford Motor ...

Wall Street is drifting Thursday as gains for fashion brands and cigarette makers help offset drops for Ford Motor and ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

The S&P 500 and the Nasdaq rose on Thursday, as investors sifted through several upbeat earnings reports while awaiting ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...